ew regimen of therapy in the treatment of Brucellosis

Phase 3

• Conditions: Brucellosis.; Brucella mellitensis; ICD-10 A23

• Registration Number: IRCT138708191441N1
• Lead Sponsor: Babol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 166

Inclusion Criteria

Inclusion criteria;all uncomplicated adult patients with brucellosis (except peripheral arthritis,sacroiliitis,epididymoorchitis).Exclusion criteria: age of less than 14 years, spondylitis, neurobrucellosis, pregnancy and receiving antibiotics more than 2 days before enrollment.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cure. Timepoint: After completion of therapy. Method of measurement: Improvement of all clinical symptoms and signs.

Secondary Outcome Measures

Name	Time	Method
Failure of therapy. Timepoint: After completion of treatment. Method of measurement: Persistence of the clinical signs and symptoms of the disease after treatment.;Relapse. Timepoint: Every three months interval for 12 months after treatment. Method of measurement: Reapearance of the clinical symptoms and signs of brucellosis during follow up period with increasing of the titers of STA or 2ME or isolation of brucella from blood culture either in symptomatic or asymptomatic cases.;Adverse effects of the drugs. Timepoint: During the course of treatment. Method of measurement: Measurement of BUN, creatinin, audial complaints.